Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235750144> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4235750144 abstract "Abstract Background Idiopathic inflammatory myopathies (IIM) was associated with a significantly higher risk of opportunistic infections that including Pneumocystis jiroveci pneumonia (PJP), a potentially fatal opportunistic infection. However, no prior studies have evaluated the PJP infection in subtypes of IIM. Objectives To investigate the incidence rate and mortality rate of PJP infection in subgroups of Idiopathic inflammatory myopathies (IIM) patients according to myopathy specific antibodies. Methods In the first part, 463 consecutive patients with IIM were prospectively followed up for a period of at least one year to analyze incidence of PJP. In the next part, we enrolled 30 consecutive PJP patients with any rheumatic disease were to identify the mortality rate and risk factors by Cox regression. Kaplan-Meier curve with log-rank test was used to access differences in survival. Results We found that the incidence rate of PJP in IIM patients is 3.0/100 person-year, while in MDA5 + DM patients is 7.5/100 person-year and in MDA5 − IIM patients is 0.7/100 person-year. (P < 0.05). PJP typically happened in the first two months for MDA5 + DM patients who have a significant decrease in the CD4 + T cell counts and Lymphocyte counts (P < 0.05). In PJP + patients, the mortality was lethally higher in MDA5 + DM patients than those with other rheumatic diseases (83.3% VS. 38.9%, P < 0.05). Unlike patients with other rheumatic diseases, MDA5 + patients seemed not to benefit from prompt anti-PJP treatment. For patients with other rheumatic diseases, anti-PJP treatment within 6 days was confirmed to crucially increased the survival (P < 0.05). Conclusion PJP has alarming high incidence and mortality in MDA5 + DM patients. Timely treatment for PJP does not improve the prognosis of this particular subtype. Therefore, the necessity of further study of PJP prophylaxis treatment in MDA5 + DM patients is verified." @default.
- W4235750144 created "2022-05-12" @default.
- W4235750144 creator A5038238118 @default.
- W4235750144 creator A5041334494 @default.
- W4235750144 creator A5049807983 @default.
- W4235750144 creator A5066089503 @default.
- W4235750144 creator A5066595006 @default.
- W4235750144 creator A5075722707 @default.
- W4235750144 date "2021-03-30" @default.
- W4235750144 modified "2023-09-25" @default.
- W4235750144 title "High Incidence and Mortality of Pneumocystis Jiroveci Infection in Anti-MDA5-Antibody Positive Dermatomyositis: Experience From a Single Center" @default.
- W4235750144 doi "https://doi.org/10.21203/rs.3.rs-344084/v1" @default.
- W4235750144 hasPublicationYear "2021" @default.
- W4235750144 type Work @default.
- W4235750144 citedByCount "0" @default.
- W4235750144 crossrefType "posted-content" @default.
- W4235750144 hasAuthorship W4235750144A5038238118 @default.
- W4235750144 hasAuthorship W4235750144A5041334494 @default.
- W4235750144 hasAuthorship W4235750144A5049807983 @default.
- W4235750144 hasAuthorship W4235750144A5066089503 @default.
- W4235750144 hasAuthorship W4235750144A5066595006 @default.
- W4235750144 hasAuthorship W4235750144A5075722707 @default.
- W4235750144 hasBestOaLocation W42357501441 @default.
- W4235750144 hasConcept C120665830 @default.
- W4235750144 hasConcept C121332964 @default.
- W4235750144 hasConcept C126322002 @default.
- W4235750144 hasConcept C159654299 @default.
- W4235750144 hasConcept C179755657 @default.
- W4235750144 hasConcept C203014093 @default.
- W4235750144 hasConcept C2777914695 @default.
- W4235750144 hasConcept C2778751314 @default.
- W4235750144 hasConcept C2779387793 @default.
- W4235750144 hasConcept C2780181341 @default.
- W4235750144 hasConcept C61511704 @default.
- W4235750144 hasConcept C71924100 @default.
- W4235750144 hasConcept C90924648 @default.
- W4235750144 hasConceptScore W4235750144C120665830 @default.
- W4235750144 hasConceptScore W4235750144C121332964 @default.
- W4235750144 hasConceptScore W4235750144C126322002 @default.
- W4235750144 hasConceptScore W4235750144C159654299 @default.
- W4235750144 hasConceptScore W4235750144C179755657 @default.
- W4235750144 hasConceptScore W4235750144C203014093 @default.
- W4235750144 hasConceptScore W4235750144C2777914695 @default.
- W4235750144 hasConceptScore W4235750144C2778751314 @default.
- W4235750144 hasConceptScore W4235750144C2779387793 @default.
- W4235750144 hasConceptScore W4235750144C2780181341 @default.
- W4235750144 hasConceptScore W4235750144C61511704 @default.
- W4235750144 hasConceptScore W4235750144C71924100 @default.
- W4235750144 hasConceptScore W4235750144C90924648 @default.
- W4235750144 hasLocation W42357501441 @default.
- W4235750144 hasOpenAccess W4235750144 @default.
- W4235750144 hasPrimaryLocation W42357501441 @default.
- W4235750144 hasRelatedWork W1972654829 @default.
- W4235750144 hasRelatedWork W1990040848 @default.
- W4235750144 hasRelatedWork W2025208206 @default.
- W4235750144 hasRelatedWork W2086794099 @default.
- W4235750144 hasRelatedWork W2135011891 @default.
- W4235750144 hasRelatedWork W2186062199 @default.
- W4235750144 hasRelatedWork W2373864009 @default.
- W4235750144 hasRelatedWork W2756421175 @default.
- W4235750144 hasRelatedWork W4235750144 @default.
- W4235750144 hasRelatedWork W4282042426 @default.
- W4235750144 isParatext "false" @default.
- W4235750144 isRetracted "false" @default.
- W4235750144 workType "article" @default.